{"name":"Werewolf Therapeutics","slug":"werewolf","ticker":"HOWL","exchange":"NASDAQ","domain":"werewolftx.com","description":"Werewolf Therapeutics is a biopharmaceutical company focused on developing engineered cytokines for the treatment of cancer. The company's lead product, WT-1126, is an engineered IL-2 receptor antagonist being developed for the treatment of solid tumors. Werewolf Therapeutics is a relatively new player in the immuno-oncology space, with a growing pipeline of promising candidates.","hq":"Cambridge, MA","founded":0,"employees":"","ceo":"Daniel J. Hicklin","sector":"Immuno-Oncology / Engineered Cytokines","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$185M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":44830000,"netIncome":-60822000,"cash":57050000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"WT-1126 patent cliff ($0.0B at risk)","drug":"WT-1126","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Werewolf Therapeutics Announces FDA Clearance of IND for WT-1126","summary":"Werewolf Therapeutics announced that the FDA has cleared the Investigational New Drug (IND) application for WT-1126, enabling the company to initiate a Phase 1 clinical trial.","drugName":"WT-1126","sentiment":"positive"},{"date":"2023-11-15","type":"earnings","headline":"Werewolf Therapeutics Reports Third Quarter 2023 Financial Results","summary":"Werewolf Therapeutics reported its third quarter 2023 financial results, with a net loss of $23.4 million and a cash balance of $143.8 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"Werewolf Therapeutics Enters into Collaboration with Merck KGaA","summary":"Werewolf Therapeutics announced a collaboration with Merck KGaA to develop and commercialize WT-1126 in combination with Merck's KEYTRUDA.","drugName":"WT-1126","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNWFNYdFdEWndfZ3l4Njcyd2FkYTJzRkNfNmRZS1dvZTZYcnNxUjNIT21aWmktMXl5NVNRMDNBdHI0bHVBR2FLcGtsOXFNSnFwbU5JZ09JMVdLMElBdmYwUXRHQ0hmXzNMVFpiYzdKZUNYNVhqQ05XMHgzWkVuNGQ0LU55ak9GbVZFTmFTd25EcHNEMDFuMzI0RzJKLUVJSzdPTFJlVUQ4aUxSclh5WFE?oc=5","date":"2026-04-02","type":"pipeline","source":"Seeking Alpha","summary":"Werewolf Therapeutics (HOWL) — My Take (NASDAQ:HOWL) - Seeking Alpha","headline":"Werewolf Therapeutics (HOWL) — My Take (NASDAQ:HOWL)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPeFNfRm45ZE9QY3N1NTJqYnd5WnRZQjNHM1pSQ1F4YWhDRFZxTVE4c2VfNkEwVUJfVzY1WW8tb2pMcDIwcjUyLUVUZ1ZQeXFwdlZoRUMtV3d1SlVXUDFpSXhpYzlYQmE5TllXQ0syaWlOdjZ0SXAzTHNQYnJibkU2bUNUYW11R00wY3gwVmtHcERUVFkxYy0wR2xEMUpqTXhYNWVrNlNDMFVxSnRWeDBNdTZ3?oc=5","date":"2026-03-27","type":"pipeline","source":"Stock Titan","summary":"Werewolf Therapeutics (HOWL) faces going‑concern risk while IL‑2 and IL‑12 candidates show early responses - Stock Titan","headline":"Werewolf Therapeutics (HOWL) faces going‑concern risk while IL‑2 and IL‑12 candidates show early responses","sentiment":"neutral"},{"date":"2026-03-27","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFBrNGQtc0R6NFRxY01tamRGMllGZGZTZUtDTkZSaUFtRlVMdXdDQXFUSUJJZVdXN1d2ZUZmZmJibi00Q2FFdDdaVjJCU3J3UWktRjZHMW1DVXhXZ1lYVXNYU1VmZ0tEXzRZ?oc=5","date":"2025-07-09","type":"regulatory","source":"MarketBeat","summary":"Werewolf Therapeutics (HOWL) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat","headline":"Werewolf Therapeutics (HOWL) FDA Approvals, PDUFA Dates & Drug Alerts 2026","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFBwcW95ckNFV2I0TkctOEstaThLbGliNV9scldadTBwWjhNY0JKdFl3M2xUeWxlSHFzRTFBMUF0WDRmMWo1Vmx4TUZ1WDRYSmpW?oc=5","date":"2023-11-03","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE5oNmUybDFEc1FCTUNWZEcyRXRuUk1QUzYwelhXQnJuaFFfUWRJemdkZkNtb3JiSXVQNHZ4ZncwSVRBS1BnRzdvYm5JOWw3X21LRGx5Ul9hRFRGTlk5?oc=5","date":"2022-05-03","type":"pipeline","source":"TradingView","summary":"HOWL Stock Price and Chart — NASDAQ:HOWL - TradingView","headline":"HOWL Stock Price and Chart — NASDAQ:HOWL","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AJBVV95cUxORlotWFB3aVNiVjdFcWZHU0FoX0V4aWduMlpib1NQQ3RrTmpZMGZLMFVaNGJCdHJ6Sml4UUpoYWxoNkVVRk44Tzk1aDhFWDJjX2lYaWdCaXlPTm1QUE9hVUZ2dzUzREc1eUNqT2xWaExYenRLRWdjYjVXakxqQ3BEVzNTM0dKR2RHM3hNYUtlYVhqWGFBamV6VWNrZXBxWm5kcDYxcVVaODdhNmM0bWtrcGpmUzBieS1KWEtuMmc4VDQ4Tk1FS0VSRDRiY2p5SU1scFJ1SFV4OFVFcGV0aXI4Y0FrM2VTaDhjNGxoM2RoVjBfU2VDaWY4TVN3bVJwcDVydklfZUd1UnJkU2FCMHFEYThiSkdtSTM5RndhM25XVFQtRTJBSGNoZ1RkODh4azN5cVVBbWpTQjV3SlkwX2RSQ0RhLWFpS2ZHQWMtU0VnMmE1aHE3ZUpCS2FkWjJhcVN2RGxUVg?oc=5","date":"2022-04-07","type":"deal","source":"PR Newswire","summary":"Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE™ Molecule - PR ","headline":"Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPN1dlcllXTHRsRUVSaTc1SlBydDB3MEJHN28xVkdJeGUwN0ZzZk4wdTNySC02VkdFMEZzZEtkclZCSjkteFN0Ym1IUWFzQ2NvODRVbUg5QWNlY0F0WXYzYnVLU3FubUlBanN2dHVtMFJQUUlXNDVXYUZCYkJ0YndoeTI3VldVdDN6WFJYRldVX3ZFeGVHeDVNb0Rlcl85TVJ3?oc=5","date":"2022-04-07","type":"pipeline","source":"Fierce Biotech","summary":"Jazz, Werewolf to howl at the moon together in $1.26B backloaded biobucks pact - Fierce Biotech","headline":"Jazz, Werewolf to howl at the moon together in $1.26B backloaded biobucks pact","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBIcUpZcG9MMk5ja2RVemNlaUVMN0JKOFNlOUhfRFVvQVNaZWdBVUVRZTNySTNPOU1xSlRpMUE3Qy1UYm9IVUk0MXlZODZ4N2dfU2pObk80b2M5dUVRbkVGX3hTcHhlbEFjdkFWYkVR?oc=5","date":"2021-08-26","type":"pipeline","source":"MarketBeat","summary":"Werewolf Therapeutics (HOWL) Short Interest & Short Float | Updated Apr 2026 - MarketBeat","headline":"Werewolf Therapeutics (HOWL) Short Interest & Short Float | Updated Apr 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPV1c4UUw3R3F1YVo2WXhXWUpZOU9nakU2eXlLZjZlR2dkb3pvRFlzdi11aFp5OVZTMVBLN28tckpHTXpWbzI3TFh0QzF5eFZacHJpMWNabHh1M01GUUZCOG5FbEJsUTI5NnNpUDRFMFM0cy1Pcmt5ZHNXV0RWUWVDcg?oc=5","date":"2021-05-01","type":"pipeline","source":"MarketBeat","summary":"Top Werewolf Therapeutics (HOWL) Competitors 2026 - MarketBeat","headline":"Top Werewolf Therapeutics (HOWL) Competitors 2026","sentiment":"neutral"}],"patents":[{"drugName":"WT-1126","drugSlug":"il-2-receptor-antagonist","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Gilead Sciences"],"therapeuticFocus":["Immuno-oncology","Engineered cytokines"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":44830000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-60822000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":57050000,"cashHistory":[],"totalAssets":69396000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}